CTE supplementation, alone or in combination with BPL1® HT, prevented MetS-induced endothelial dysfunction (p < 0.05), whereas supplementation with BPL1® HT alone did not have any impact either in the vascular response to Ach or the vascular response to insulin. The gene discussed is FGFR3; the disease is metabolic syndrome.